These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15283142)

  • 1. [Development of novel angiogenesis inhibitors targeting VEGF (vascular endothelial growth factor) for cancer chemotherapy].
    Kakeya H; Osada H
    Nihon Rinsho; 2004 Jul; 62(7):1264-70. PubMed ID: 15283142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
    Osada H; Kakeya H
    Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ; Ellis LM
    J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S; Schiller JH
    Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
    Tonra JR; Hicklin DJ
    Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenic therapy against gastrointestinal tract cancers.
    Iwasaki J; Nihira S
    Jpn J Clin Oncol; 2009 Sep; 39(9):543-51. PubMed ID: 19531544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-angiogenesis targeting drugs: a review].
    Jia K; Li J
    Ai Zheng; 2008 Apr; 27(4):442-6. PubMed ID: 18423135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of vascular endothelial growth factor in kidney and prostate cancer.
    Delongchamps NB; Peyromaure M
    Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumoral angiogenesis: review of the literature.
    Khosravi Shahi P; Fernández Pineda I
    Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.